62 Result(s)
within
English
Medicine & Public Health
Metabolic Diseases
Pharmacology/Toxicology
Yi** **
Conference Paper
-
Chapter and Conference Paper
Comparative Metabolic Availability of Glucose and Sucrose and the Effect of Acarbose on Sucrose Utilization During Exercise in Type I Diabetic Patients
We have previously shown that glucose (G) and sucrose (S) given orally during exercise of prolonged duration and moderate intensity are perfectly available metabolic substrates. Moreover, in normal humans, we ...
-
Chapter and Conference Paper
Discussion
-
Chapter and Conference Paper
Effects of Acarbose on Serum Lipids and Lipoproteins in Healthy Individuals During Prolonged Administration of a Fiber-Free Diet
The effects of the disaccharidase inhibitor acarbose on total triglycerides (TG), total cholesterol (TC), very low density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HD...
-
Chapter and Conference Paper
Effect of Acarbose on Fecal Short-Chain Fatty Acid Excretion in Man
The effect of the glucosidase inhibitor acarbose (BAY g 5421) on colonic carbohydrate fermentation was investigated in 11 healthy volunteers. Anaerobic bacteria in the ascending colon degrade malabsorbed starc...
-
Chapter and Conference Paper
Effects of Sucrose Meal on Insulin Requirement in IDDM and its Modulation by Acarbose
We have studied in patients with insulin-dependent diabetes mellitus (IDDM) the effects of a sucrose meal on glucose gut absorption, glucose turnover, insulin requirement, and the modulation of the latter by a...
-
Chapter and Conference Paper
Panel Discussion: Future Aspects of α-Glucosidase Inhibition
-
Chapter and Conference Paper
The Influence of Acarbose Dosage Scheme on Intestinal Symptoms and Intestinal Transit Time in Healthy Volunteers
Intestinal symptoms such as flatulence, meteorism, and diarrhea may be induced as a result of the α-glucosidase inhibition caused by acarbose. The aim of this study was to compare the intestinal effects after ...
-
Chapter and Conference Paper
Acarbose in Non-insulin-dependent Diabetes Mellitus: Short-term Studies in Combination with Oral Agents
Type II diabetes mellitus (non-insulin-dependent diabetes mellitus, NIDDM) is a disease with increasing prevalence in western civilized countries. One reason for this is that the incidence of type II diabetes ...
-
Chapter and Conference Paper
Discussion
-
Chapter and Conference Paper
Discussion
-
Chapter and Conference Paper
Metabolic Effects of Acarbose in Normal and NIDDM Subjects
In order to study the metabolic effects of the α-glucosidase inhibitor acarbose, eight normal subjects (four male and four female) and eight subjects with non-insulin- dependent diabetes mellitus (NIDDM) (six ...
-
Chapter and Conference Paper
Metabolic Control in Type II Diabetes with Long-Term Acarbose Therapy: A Double-Blind Study
Several studies have shown that acarbose improves the metabolic control of type II diabetic patients when administered with sulfonylurea treatment. The aim of the present study was to evaluate the potential be...
-
Chapter and Conference Paper
Comparison of the Action of an α-Glucosidase Inhibitor (Acarbose) and a Sulfonylurea Preparation (Glisoxepide) in Non-insulin-dependent Diabetics
The efficacy of a 4-week treatment with acarbose compared to that with glisoxepide was studied in a controlled group comparison in 40 diabetics treated with diet alone. The median age of the patients was 70 (m...
-
Chapter and Conference Paper
Effect of Acarbose in Type II Diabetics Treated with Diet Alone, with Diet, and with Sulfonylurea, Diet, and Insulin
Glucosidase inhibition with acarbose, a new therapeutic approach to the treatment of diabetes mellitus, has proven to be effective and well tolerated in over 5000 type I and type II diabetics. In three double-...
-
Chapter and Conference Paper
Multicenter Clinical Trial up to 15 Months: Efficacy and Tolerability of Acarbose in Glibenclamide-Treated Type II Diabetics with Secondary Sulfonylurea Failure Versus Glibenclamide Therapy Alone
The principle of delaying the enteral digestion of carbohydrates by inhibiting intestinal glucosidases is a successful new therapeutic approach for the treatment of diabetes mellitus. When used either as a mon...
-
Chapter and Conference Paper
Long-Term Effects of Acarbose Treatment on Postprandial Glucose, Pancreatic and Gut Hormone Responses and Fasting Serum Lipids in Non-insulin-Dependent Diabetics on Sulphonylureas
Seventeen non-insulin-dependent diabetics, poorly controlled by diet and sulphonylurea treatment, participated in a long-term (20–52 weeks) trial on the effect of additional treatment with acarbose, 100 mg thr...
-
Chapter and Conference Paper
Comparative Effects of Acarbose on Glycemia, Weight Gain, and Serum Lipids in Adult Male and Female Diabetic Wistar Fatty Rats
To determine the effects of delayed carbohydrate (CHO) absorption on glycemic status, weight gain (WG), and serum lipid profiles (cholesterol, triglycerides) in adult obese-diabetic rats with chronic obesity, ...
-
Chapter and Conference Paper
Effectiveness and Tolerability of the α-Glucosidase Inhibitor Acarbose in NIDDM Patients with Elevated Liver Enzyme Activity
Acarbose is a glucosidase inhibitor which exerts its activities within the gastrointestinal tract on brush-border digestion and absorption of sucrose and maltose. Only 1%–2% of the drug is absorbed from the in...
-
Chapter and Conference Paper
Toxicology of Acarbose, with Special Reference to Long-term Carcinogenicity Studies
Acarbose is a glucosidase inhibitor which exerts its activities within the gastrointestinal tract of animals and humans [1]. The drug delays glucose absorption and thus represents a new therapeutical concept i...
-
Chapter and Conference Paper
A Preclinical Study on the Effects of Acarbose on Mice Rendered Obese with Gold Thioglucose
The effect of acarbose has been studied in mice made obese and hyperinsulinemic by gold thioglucose (GTG). One month after GTG administration, when obesity started to develop, mice were treated orally with aca...
